BioCardia Inc./$BCDA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an off the shelf cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).
Ticker
$BCDA
Sector
Primary listing
Employees
19
Headquarters
Website
BioCardia Inc. Metrics
BasicAdvanced
$11m
-
-$0.95
0.55
-
Price and volume
Market cap
$11m
Beta
0.55
52-week high
$2.45
52-week low
$0.78
Average daily volume
5.7m
Financial strength
Current ratio
0.41
Quick ratio
0.35
Total debt to equity
-38.649
Profitability
EBITDA (TTM)
-7.803
Management effectiveness
Return on assets (TTM)
-252.00%
Return on equity (TTM)
601.31%
Valuation
Price to book
-9.73
Price to tangible book (TTM)
-9.73
Price to free cash flow (TTM)
-1.039
Free cash flow yield (TTM)
-96.22%
Free cash flow per share (TTM)
-0.912
Growth
Earnings per share change (TTM)
-60.69%
3-year earnings per share growth (CAGR)
-54.11%
10-year earnings per share growth (CAGR)
-46.00%
BioCardia Inc. News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs